U.S FDA issues draft guidance for abuse-deterrent opioid generics

(Reuters) - The U.S. Food and Drug Administration issued draft guidance on Thursday for abuse-deterrent opioid generics, including a recommendation that studies be conducted to demonstrate that generic opioids are no less abuse-deterrent than branded drugs.